Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.37 |
| ▸ | FNTB | P49356 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 4/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397445 | 1.00 | FNTA (0.37) | FNTAFNTBANPEPLNPEPCASP3 | |
| SCHEMBL31049654 | 0.96 | CTSD (0.38) | FNTAFNTBANPEPLNPEPCASP3 | |
| SCHEMBL29881377 | 0.93 | CTSD (0.35) | FNTAFNTBANPEPLNPEPCASP3 | |
| SCHEMBL30738394 | 0.93 | BACE1 (0.41) | CASP3CASP7BACE1CTSD | |
| SCHEMBL29853431 | 0.93 | BACE1 (0.41) | CASP3CASP7BACE1CTSD | |
| SCHEMBL79320 | 0.92 | ACE (0.36) | — | |
| SCHEMBL78173 | 0.92 | ACE (0.36) | — | |
| SCHEMBL78174 | 0.92 | ACE (0.36) | — | |
| SCHEMBL29697029 | 0.91 | ANPEP (0.34) | ANPEPLNPEPBACE1DPP3 | |
| SCHEMBL30974548 | 0.90 | BACE1 (0.35) | FNTAFNTBCASP3CASP7BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2018140580-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | 2C TECH CORP. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | UACA, CRYAA, CRYAB | FNTA 3228/4885FNTB 3508/4885ANPEP 761/4885 |
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | CHRNA1, CHRNB1, NPY1R | FNTA 4333/4885FNTB 4056/4885ANPEP 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.